Application of traditional Chinese medicine composition in preparation of medicine for inhibiting novel coronavirus

By developing a traditional Chinese medicine composition composed of medicinal materials such as savoniae, the disease transformation and treatment problems of novel coronavirus pneumonia were solved, and the inhibition of novel coronavirus and pathological changes were improved, which significantly prolonged the survival of mice. Days and relieved symptoms of pneumonia.

CN118987149AInactive Publication Date: 2024-11-22GUANGZHOU UNIRISE PHARM CO LTD +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310572922.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Pneumonia caused by the new coronavirus has the characteristics of acute onset, severe condition and high mortality rate. Existing traditional Chinese medicine preparations are difficult to effectively inhibit the transformation of the disease and treat severe and critical patients.

Method used

Develop a traditional Chinese medicine composition, composed of medicinal materials such as saffron cerevisia, saffron vera, patchouli, perilla leaves, Magnolia officinalis, cardamom, ginger, licorice, etc., and make medicine through specific ratios and preparation methods. , used to inhibit the spread of the novel coronavirus and improve pathological changes.

Benefits of technology

The Chinese medicine composition significantly inhibits the novel coronavirus in vitro, improves interstitial pneumonia and vascular/peribronchiolitis cell infiltration caused by infection, prolongs the average survival days in mice, and reduces pulmonary bleeding and inflammation pathological changes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987149A_ABST
    Figure CN118987149A_ABST
Patent Text Reader

Abstract

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for inhibiting novel coronavirus. The composition has an obvious inhibiting effect on the novel coronavirus in vitro. In addition, the traditional Chinese medicine composition has a certain improvement effect on interstitial pneumonia, vascular / peribronchial inflammation cell infiltration and pulmonary hemorrhage pathological changes caused by novel coronavirus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of Chinese medicine preparations, and specifically relates to the use of a Chinese medicine composition in the preparation of drugs for inhibiting the new coronavirus. Background Art

[0002] Compound Elsholtzia water is a Yi medicine. It originated from the classic recipe Elsholtzia drink in the Song Dynasty's "Taiping Huimin Hejiju Fang". It is a traditional Chinese medicine preparation composed of 9 medicinal materials: Elsholtzia crusgalli, Indigofera ternata, Patchouli, Perilla leaves, Magnolia bark, Cardamom, Costus root, ginger, and Licorice.

[0003] The main drug is Elsholtzia crucifera, which is mainly produced in Honghe Prefecture, Mengzi, Jianshui and other places. People often call it "wild elm, which has the effects of sweating, relieving exterior pathogens and removing dampness. It has a fragrant aroma, enters the spleen and stomach to remove dampness and relieve heat, and is called "the medicine for relieving exterior pathogens in summer". It has a long history of traditional folk medicine, and has been recorded as a medicine in many documents in Yunnan. Its main effects are sweating, dispelling wind and relieving exterior pathogens, removing dampness, regulating qi and strengthening spleen, and eliminating accumulation and digestion. The assistant drugs are patchouli and perilla leaves, which have the effects of removing dampness and relieving exterior pathogens, warming the stomach and promoting qi, and helping the main drug to disperse exterior pathogens, and cooperate with the main drug to relieve exterior pathogens and remove dampness, clear the head, and digest food and regulate qi. The adjuvant drugs are orchid, magnolia bark, cardamom, and costus root, which can promote qi and relieve pain, dispel filth and clear the middle, relieve tendons and dispel cold, strengthen spleen and digestion, eliminate tendon and vein stiffness, sore limbs, gastrointestinal distension and stop diarrhea. The guiding herbs licorice and ginger harmonize the various herbs, clear the exterior and interior, guide the herbs to the meridians, warm the middle and dispel cold, and help stimulate the appetite and stop vomiting.

[0004] Therefore, the prescription of compound Elsholtzia water has the functions of aromatic dehumidification, invigorating the spleen and stomach, and is used to treat the invasion of unhealthy qi of the four seasons into the human body or the obstruction of turbid qi in the middle jiao, resulting in symptoms such as mental depression, fullness and pain in the abdomen, nausea and vomiting. Clinical application has proved that it can effectively treat summer-heat cold, gastrointestinal cold, acute gastroenteritis, cold and other diseases.

[0005] Pneumonia caused by the new coronavirus is an acute respiratory infectious disease caused by SARS-CoV-2 infection. Its symptoms are mainly fever, fatigue, and dry cough. In severe cases, breathing difficulties may occur. A small number of patients have symptoms such as nasal congestion, runny nose, and diarrhea. In severe cases, acute respiratory distress syndrome, septic shock, metabolic acidosis, and coagulation dysfunction may develop rapidly. Compared with diseases caused by other viruses, pneumonia caused by the new coronavirus has the characteristics of rapid onset, severe condition, and high mortality rate.

[0006] Traditional Chinese medicine believes that pneumonia caused by the new coronavirus belongs to the category of "epidemic disease" in traditional Chinese medicine. The cause of the disease is infection with the evil qi of the epidemic, and the disease is located in the lungs. Based on this, the combination and formulation of medicines can reduce the transformation of mild and ordinary patients to severe and severe to critical cases, and improve the treatment effect on severe and critical patients. Based on this, it is very necessary to develop more traditional Chinese medicine compositions for inhibiting the new coronavirus. Summary of the invention

[0007] The purpose of the present invention is to provide an application of a traditional Chinese medicine composition in the preparation of drugs for inhibiting the new coronavirus.

[0008] The Chinese medicine composition is made of the following raw materials in the following weight proportions:

[0009] 85-120 parts of Elsholtzia crusgalli, 6-25 parts of Indigofera serrulata, 20-60 parts of Patchouli, 35-60 parts of Perilla leaves, 5-20 parts of Magnolia officinalis, 10-30 parts of Cardamom, 5-15 parts of Aucklandia lappa, 5-15 parts of Ginger, and 2-10 parts of Licorice.

[0010] Preferably, the Chinese medicine composition is made of the following raw materials in the following weight proportions:

[0011] 100 parts of Elsholtzia crusgalli, 10 parts of Indigofera scabra, 50 parts of Patchouli, 50 parts of Perilla leaves, 10 parts of Magnolia officinalis, 15 parts of Cardamoms, 10 parts of Aucklandia lappa, 10 parts of Ginger, 4 parts of Liquorice.

[0012] In some embodiments, the drug is composed of a traditional Chinese medicine composition and a pharmaceutically acceptable excipient, and the excipient is preferably ethanol.

[0013] The Chinese medicine composition is prepared by the following method:

[0014] In some embodiments, according to the ratio, Elsholtzia ciliata, Patchouli, Perilla leaf, Cardamom, Magnolia officinalis, ginger and licorice are weighed, ground into coarse powder respectively, boiled with water for 2 hours, and volatile oil is collected at the same time, filtered, and the filtrate is set aside. The residue is boiled with water twice, each time for 2 hours, the decoction is combined, filtered, combined with the above filtrate, concentrated into a clear paste, added with ethanol and stirred, allowed to stand for 3 to 5 hours, and the supernatant is filtered for use; separately take Indigofera ternata and Costus root, grind into coarse powder respectively, use 60% ethanol as solvent, percolate slowly, set the initial percolate aside, continue to collect the subsequent percolate, recover the ethanol and combine it with the initial percolate; combine the above clear paste and percolate, add volatile oil, mix well, add water to adjust the total amount to 1000 ml, and obtain.

[0015] In some embodiments, the drug is prepared by conventional Chinese medicine preparation methods into any commonly used dosage form, such as tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, powders, capsules, soft capsules, pills, granules, oral liquids, granules, pellets, micropills, intramuscular injections, drip injections, pastes, ointments, plasters, etc., preferably oral liquids.

[0016] In some embodiments, according to the common technical knowledge and prior art in the art, the treatment involved in the present invention includes prevention and treatment of a given disease or symptom. Moreover, the amount of the pharmaceutically active extract of the present invention required for treatment should vary according to the nature of the disease being treated and the patient's condition, or according to the doctor's advice.

[0017] The new use of the Chinese medicine composition provided by the present invention has the following advantages:

[0018] The composition of the present invention has a significant inhibitory effect on the novel coronavirus in vitro. In addition, it has a certain improvement effect on interstitial pneumonia, vascular / bronchiolar periinflammatory cell infiltration, and pulmonary hemorrhage pathological changes caused by novel coronavirus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 These are the lung tissue pathology results of mice infected with SARS-CoV-2 virus in the negative control group. Among them, the bronchial structures at all levels of the lungs are normal, the alveolar cavity and interstitial blood vessels are not dilated or contracted, and no inflammatory cells are seen.

[0020] Figure 2 These are the lung tissue pathology results of mice infected with SARS-CoV-2 virus in the virus model control group, including moderate hemorrhage / congestion in the lungs, moderate interstitial pneumonia, and severe alveolar protein fluid infiltration.

[0021] Figure 3 These are the pathological results of lung tissue in mice infected with SARS-CoV-2 virus in the compound Elsholtzia group, showing mild interstitial pneumonia in the lungs. DETAILED DESCRIPTION

[0022] The present invention is further described below in conjunction with specific examples and accompanying drawings, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0023] Example 1 In vitro inhibition of novel coronavirus experiment

[0024] 1. Experimental materials:

[0025] 1. Test drug: Compound Elsholtzia water, provided by Guangzhou Yipinhong Biopharmaceutical Co., Ltd. (Batch No.: 10621011), content (concentration): 1 mL is equivalent to 2.59 g of crude drug; specification: 10 mL per bottle. Prepared according to the following method:

[0026] 1) 1000g of Elsholtzia crusgalli, 100g of Indigofera crookedii, 500g of Patchouli, 500g of Perilla leaf, 100g of Magnolia officinalis, 150g of Cardamom, 100g of Aucklandia lappa, 100g of Ginger, and 40g of Licorice for later use;

[0027] 2) According to the proportion, weigh Elsholtzia ciliata, Patchouli, Perilla leaf, Cardamom, Magnolia officinalis, ginger and licorice, grind them into coarse powder respectively, boil them in water for 2 hours, collect volatile oil at the same time, filter, and set aside the filtrate, boil the residue in water for 2 times, each time for 2 hours, combine the decoction, filter, and combine with the above filtrate, concentrate into a clear paste with a relative density of about 1.13, add an equal amount of ethanol and stir, let stand for 3 to 5 hours, and filter the supernatant for use; separately take Indigofera crookedii and Aucklandia lappa, grind them into coarse powder respectively, use 60% ethanol as solvent, slowly percolate, set the initial percolate aside, continue to collect the subsequent percolate, recover the ethanol and combine it with the initial percolate; combine the above clear paste and percolate, add volatile oil, mix, and add water to adjust the total amount to 1000ml, and obtain.

[0028] Preparation method of different concentrations: Take a certain volume of compound Elsholtzia water, add a certain volume of pure water, mix and dilute to a certain concentration of compound Elsholtzia water solution.

[0029] 2. Experimental cells: VeroE6 cells, maintained by the Virus Laboratory of the State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health.

[0030] 3. Experimental virus: SARS-CoV-2, isolated from a patient's throat swab, stored in the P3 laboratory of Guangzhou Customs Technology Center (Highly Pathogenic Microorganisms Laboratory, State Key Laboratory of Respiratory Diseases), stored in an ultra-low temperature refrigerator at -80°C. Culture method: Virus isolation and culture were performed in Vero E6 cell vectors using DMEM medium containing 2% fetal bovine serum.

[0031] 2. Determine the inhibitory activity of the tested drugs against the novel coronavirus

[0032] S1. Use Vero E6 cells to plate 48-well cell plates, with 10 cells per well. 5 cells.

[0033] S2. When the cells grow to 75% confluence, add 5 μL of 10 5 PFU / mL SARS-CoV-2 virus.

[0034] S3. After incubation at room temperature for 1 h, discard the viral supernatant and wash the cells twice.

[0035] S4. Add the test drug (the concentrations after addition are 5.0 mg / ml, 2.5 mg / ml, and 1.25 mg / ml, respectively), and add an equal amount of culture medium to the blank group.

[0036] S5. 24 hours after virus infection, collect the supernatant from each well and extract RNA.

[0037] S6. Add 350 μL of lysis solution to the wells, shake at 50 r / min for 5 min, then add 200 μL of anhydrous ethanol to the wells, shake at 50 r / min for 5 min.

[0038] S7. Take out the solution in the well and transfer it to the RNA extraction column. Centrifuge at 12000r / min for 2min. After purification, add RNAwashing buffer 1 and centrifuge at 12000r / min for 30s.

[0039] S8. Add RNA washing buffer 2 and centrifuge at 12000r / min for 1min to remove residual RNA washing buffer. Add 50μL DEPC water and centrifuge at 12000r / min for 2min. Take 5μL RNA sample and perform fluorescence quantitative experiment.

[0040] Virus inhibition rate (%) = (1-RNA copy number of test group wells / RNA copy number of blank group wells) × 100%. The results are shown in Table 1. The results show that compound Elsholtzia water has a significant in vitro inhibitory effect on SARS-CoV-2.

[0041] Table 1 Inhibition rate of tested drugs

[0042] Group Viral suppression rate The test drug was tested at a concentration of 1.25 mg / ml 65.2% The test drug was tested at a concentration of 2.5 mg / ml 71.8% The test drug was tested at a concentration of 5.0 mg / ml 80.5%

[0043] Example 2 Study on the effect of compound Elsholtzia water on preventing novel coronavirus infection in hACE2 transgenic mice

[0044] 1. Experimental materials:

[0045] 1. The test drug (compound Elsholtzia water), experimental cells, and experimental viruses are the same as those in Example 1.

[0046] 2. Experimental Animals

[0047] hACE2 transgenic C57BL / 6 mice are SAR-CoV-2 virus-susceptible animals used in anti-novel coronavirus pharmacodynamics trials, and their grade meets the national laboratory animal grade requirements.

[0048] Basic Situation

[0049] Animal strain: hACE2 mouse

[0050] Age of transfer: 6 to 8 weeks

[0051] Gender: All males

[0052] Animal weight range at transfer: 20.4~24.7g

[0053] Source: Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.

[0054] Grade: SPF grade

[0055] Experimental Animal Production License Number: SCXK(Su)2018-0008, valid until June 5, 2023, issued by the Jiangsu Provincial Department of Science and Technology; Experimental Animal Quality Certificate Number: No.320727211100330185, 320727211100329936.

[0056] Number of experimental animals Reason for use: This study designed 3 experimental groups, except for the normal control group with 6 animals, the remaining groups each had 8 animals. The number of animals used in this experiment can meet the requirements of statistical testing.

[0057] 3. Test materials

[0058] CMC-Na: Manufacturer: Shanghai Aladdin Biochemical Technology Co., Ltd. The main reagent information used in the end is presented in the summary report. 0.5% CMC-Na solution (taking the preparation of 100mL as an example): Weigh 0.5g CMC-Na, add pure water to 100mL, and dissolve.

[0059] Main reagents:

[0060] Table 2 List of main reagents

[0061]

[0062] 2. Test methods

[0063] 1. Test and control dosage and group design

[0064] Table 3 Groups and dosage design list

[0065]

[0066] A, B, and H represent the normal control group, virus model control group, and compound Elsholtzia water-administered group, respectively.

[0067] 2. Administration route, method, dosage, frequency and duration of the test and reference substances

[0068] 1) Administration route: All groups of animals were given the drug by oral gavage.

[0069] 2) Dosage frequency and duration: The normal control group and the virus model control group did not receive any medication; the compound Elsholtzia water-administered group received medication twice a day before virus infection and continued to receive medication after infection for 10 consecutive days.

[0070] 3. Pretreatment and / or preparation of test and reference substances

[0071] Taking the preparation of 10 mL as an example, absorb 4.865 mL of compound Elsholtzia water, add 5.135 mL of pure water, mix well, and obtain a solution with a concentration of 1.26 g crude drug / mL.

[0072] 4. Test methods

[0073] Thirty qualified hACE2 mice were randomly divided into three groups according to age and weight: normal control group, virus model control group, and compound Elsholtzia water administration group. Except for the 6 animals in the normal control group, the other groups had 8 animals in each group, all of which were male. The day of grouping was recorded as D0. After grouping, each group was administered with drugs as planned, and the animals in the compound Elsholtzia water administration group were administered with drugs from D2 to D11. On the 5th day of administration (D5 or D6), except for the mice in the normal control group, the mice in other groups were infected with 10 drops of nasal drops. 5 PFU of SARS-CoV-2 virus. The death of animals within 5 days after infection was recorded, and the average survival days and mortality rate within 5 days were calculated. The lungs of moribund animals were euthanized or the dead animals were dissected; all surviving animals were euthanized and dissected on the 5th day after infection (D10 or D11). The left lung tissue was fixed for histopathological examination (hematoxylin-eosin staining method).

[0074] 5. Test results

[0075] 5.1 Effect on the protection against death in mice infected with SARS-CoV-2 virus

[0076] The survival results of each group of animals are shown in Table 4. After the fourth day of infection (D10), 100% of the mice in the virus model group died. After the fifth day of infection (D11), the protective effect of the compound Elsholtzia water administration group on mice infected with the new coronavirus SARS-CoV-2 was 42.86% (3 / 7). The average survival days of mice in the compound Elsholtzia water administration group were 4.43, which was significantly different from the average survival days of 3.88 days in the virus model group (P<0.05).

[0077] Table 4 Effect of compound Elsholtzia water on the protection of mice from death caused by SARS-CoV-2 virus infection

[0078]

[0079] 5.2 Results of lung histological examination of mice infected with SARS-CoV-2 virus

[0080] The results of lung tissue pathological examination showed (Table 5), compared with the normal control group (see Figure 1 Compared with the control group, the lung tissues of the animals in the model group showed pulmonary hemorrhage / congestion, interstitial pneumonia (phagocyte infiltration / protein exudation), alveolar protein exudation, vascular / bronchiolar peri-inflammatory cell infiltration, bronchial mucosal degeneration / necrosis, and shedding, as shown in Figure 2. Figure 2Combined with the animal proportion and the degree of lesions, compared with the virus model control group, the lesions of the compound Elsholtzia water group at a dose of 50.51g / kg were alleviated, especially for the interstitial pneumonia, vascular / bronchiolar inflammatory cell infiltration, and pulmonary hemorrhage caused by the new coronavirus (SARS-CoV-2) infection. Figure 3 The degree of histopathological changes “-, ±, +, ++, +++” represent normal, slight, mild, moderate and severe, respectively.

[0081] Table 5 Statistical table of lung histological examination results

[0082]

[0083] Obviously, the above embodiments are merely examples for clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from them are still within the protection scope of the invention.

Claims

1. Use of a Chinese medicine composition in the preparation of drugs for inhibiting the new coronavirus, The Chinese medicine composition is made of the following raw materials in the following weight proportions: 85-120 parts of Elsholtzia crusgalli, 6-25 parts of Indigofera serrulata, 20-60 parts of Patchouli, 35-60 parts of Perilla leaves, 5-20 parts of Magnolia officinalis, 10-30 parts of Cardamom, 5-15 parts of Aucklandia lappa, 5-15 parts of Ginger, and 2-10 parts of Licorice.

2. The use according to claim 1, characterized in that The Chinese medicine composition is made of the following raw materials in the following weight proportions: 100 parts of Elsholtzia crusgalli, 10 parts of Indigofera scabra, 50 parts of Patchouli, 50 parts of Perilla leaves, 10 parts of Magnolia officinalis, 15 parts of Cardamoms, 10 parts of Aucklandia lappa, 10 parts of Ginger, 4 parts of Liquorice.

3. The use according to any one of claims 1 to 2, wherein the medicine is composed of a Chinese medicine composition and pharmaceutically acceptable excipients.

4. The use according to any one of claims 1 to 2, characterized in that: The Chinese medicine composition is prepared by the following method: Weigh Elsholtzia ciliata, Patchouli, Perilla leaf, Cardamom, Magnolia officinalis, ginger and licorice according to the proportion, grind them into coarse powder respectively, boil and extract for 2 hours, collect volatile oil at the same time, filter and set aside the filtrate, boil and extract the residue in water for 2 more times, each time for 2 hours, combine the decoction, filter, combine with the above filtrate, concentrate into a clear paste, add ethanol and stir well, let stand for 3 to 5 hours, filter and set aside the supernatant; take Indigofera ternata and Costus root, grind them into coarse powder respectively, use 60% ethanol as solvent, percolate slowly, set the initial percolate aside, continue to collect the subsequent percolate, recover the ethanol and combine it with the initial percolate; combine the above clear paste and percolate, add volatile oil, mix well, add water to adjust the total amount to 1000ml, and obtain the product.